Related Experiment Video
Updated: Jul 19, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
A M Mahedi Hasan1, Paolo Cremaschi1, Daniel Wetterskog1
1University College London Cancer Institute, London, UK.
Abstract:
Despite initial responses to hormone treatment, metastatic prostate cancer invariably evolves to a lethal state. To characterize the intra-patient evolutionary relationships of metastases that evade treatment, we perform genome-wide copy number profiling and bespoke approaches targeting the androgen receptor (AR) on 167 metastatic regions from 11 organs harvested post-mortem from 10 men who died from prostate cancer. We identify diverse and patient-unique alterations clustering around the AR in metastases from every patient with evidence of independent acquisition of related genomic changes within an individual and, in some patients, the co-existence of AR-neutral clones. Using the genomic boundaries of pan-autosome copy number changes, we confirm a common clone of origin across metastases and diagnostic biopsies, and identified in individual patients, clusters of metastases occupied by dominant clones with diverged autosomal copy number alterations. These autosome-defined clusters are characterized by cluster-specific AR gene architectures, and in two index cases are topologically more congruent than by chance (p-values 3.07 × 10-8 and 6.4 × 10-4). Integration with anatomical sites suggests patterns of spread and points of genomic divergence. Here, we show that copy number boundaries identify treatment-selected clones with putatively distinct lethal trajectories.
Insights
Metastatic prostate cancer evolves resistance through diverse genetic changes around the androgen receptor (AR). Copy number alterations reveal distinct clones within patients, suggesting varied lethal trajectories and treatment resistance.
Area of Science:
- Genomics
- Cancer Biology
- Evolutionary Medicine
Background:
- Metastatic prostate cancer often becomes lethal despite initial hormone therapy.
- Understanding treatment resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To characterize the genomic evolution of treatment-resistant prostate cancer metastases within individual patients.
- To identify distinct clones and their evolutionary relationships in lethal prostate cancer.
Main Methods:
- Genome-wide copy number profiling of 167 metastatic regions from 10 patients.
- Targeted analysis of androgen receptor (AR) gene alterations.
- Utilizing genomic boundaries of copy number changes to define clonal clusters.
Main Results:
- Identified diverse, patient-unique AR alterations in metastases, indicating independent evolution.
- Confirmed a common origin clone across metastases and diagnostic samples.
- Discovered clusters of metastases with distinct autosomal copy number alterations and AR gene architectures.
- Demonstrated topological congruence of autosome-defined clusters, suggesting shared evolutionary paths.
Conclusions:
- Copy number boundaries can identify treatment-selected clones with distinct lethal trajectories.
- Genomic divergence patterns correlate with anatomical spread and treatment resistance.
- Intra-patient heterogeneity in AR alterations drives lethal prostate cancer evolution.

